Wolfe Research initiated coverage of Pfizer (PFE) with an Underperform rating and $25 price target While it can be challenging to move the needle on large pharma companies, Wolfe has started to see Pfizer take action with its cost alignment program that was initiated at the beginning of the year, the analyst tells investors in a research note. Still, the firm argues the true driver of value creation for Pfizer will be revenue growth, and it doesn’t count enough mega-blockbusters in Pfizer’s new product cycle to fill the revenue hole from upcoming patent expirations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PFE:
- Vaccine makers fall after Trump nominates RFK to head HHS
- Trump names Robert Kennedy as Secretary of Health and Human Services
- Pfizer initiated with an Underperform at Wolfe Research
- Notable open interest changes for November 13th
- Pfizer Considers Selling Hospital Unit to Free Up Cash and Reduce Debt
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
